Guggenheim Initiates Coverage On CytomX Therapeutics with Buy Rating, Announces Price Target of $10
Benzinga Newsdesk 9 months ago
NewsPrice TargetInitiationAnalyst Ratings
Guggenheim analyst Michael Schmidt initiates coverage on CytomX Therapeutics (NASDAQ:CTMX) with a Buy rating and announces Price Target of $10.
Guggenheim analyst Michael Schmidt initiates coverage on CytomX Therapeutics (NASDAQ:CTMX) with a Buy rating and announces Price Target of $10.